STOCK TITAN

[Form 4] MetLife, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

MetLife director Diana McKenzie reported a small insider acquisition under Form 4. On 09/09/2025 she received 158 shares of MetLife common stock at an imputed price of $79.29 through reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors. After the transaction her beneficial ownership is reported as 22,223 shares held directly. The Form 4 was filed as a single reporting person filing and signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.

La direttrice di MetLife, Diana McKenzie, ha riferito un piccolo acquisto da insider ai sensi del modulo 4. Il 09/09/2025 ha ricevuto 158 azioni comuni MetLife a un prezzo imputato di 79,29 dollari per azione tramite il reinvestimento dei dividendi nell'ambito del MetLife Deferred Compensation Plan per i direttori non esecutivi. Dopo la transazione la sua titolarità beneficiaria è riportata come 22.223 azioni detenute direttamente. Il modulo 4 è stato presentato come unica persona reportante e firmato per conto del reportante da un mandatario con procura il 11/09/2025.

La directora de MetLife, Diana McKenzie, informó una pequeña adquisición de insider bajo el Formulario 4. El 09/09/2025 recibió 158 acciones de MetLife a un precio imputado de 79,29 dólares por acción mediante reinversión de dividendos en el MetLife Deferred Compensation Plan para Directores No Ejecutivos. Tras la operación, su titularidad beneficiaria se reporta en 22.223 acciones, directamente poseídas. El Formulario 4 se presentó como una única persona reportante y fue suscrito en nombre de la persona reportante por un mandatario con poder el 11/09/2025.

MetLife 이사 다이아나 맥켄지(Diana McKenzie)가 Form 4에 따른 소액 내부자 거래를 보고했습니다. 2025년 9월 9일 she는 MetLife 보통주 158주를 주당 79.29달러의 가상 가격으로 배당 재투자를 통해 받았습니다(비경영진 이사를 위한 MetLife 연금 계획). 거래 후 그녀의 유익 소유권은 직접 보유한 22,223주로 보고됩니다. Form 4는 단일 보고인으로 제출되었고 보고인 대리인이 2025년 9월 11일에 서명했습니다.

La directrice de MetLife, Diana McKenzie, a signalé une faible acquisition d’initié selon le formulaire 4. Le 09/09/2025, elle a reçu 158 actions ordinaires MetLife à un prix imputé de 79,29 USD par action grâce au réinvestissement des dividendes dans le cadre du MetLife Deferred Compensation Plan pour les administrateurs non dirigeants. Après la transaction, sa propriété bénéficiaire est déclarée à 22 223 actions détenues directement. Le formulaire 4 a été déposé en tant que personne déclarante unique et signé au nom de la personne déclarant par un mandataire le 11/09/2025.

MetLife-Direktorin Diana McKenzie meldete eine geringe Insider-Kauf unter Formular 4. Am 09/09/2025 erhielt sie 158 MetLife Stammaktien zu einem imputierten Preis von 79,29 USD pro Aktie durch Reinvestition von Dividenden im Rahmen des MetLifeDeferred Compensation Plan für nicht geschäftsführende Direktoren. Nach der Transaktion wird ihr wirtschaftliches Eigentum mit 22.223 Aktien gemeldet, direkt gehalten. Das Formular 4 wurde als Einzelmeldender eingereicht und am 11/09/2025 im Namen der meldenden Person von einem Bevollmächtigten unterzeichnet.

أفادت مديرة MetLife ديانا ماكنزي بعملية شراء داخلية صغيرة بموجب النموذج 4. في 09/09/2025 استلمت 158 سهماً من أسهم MetLife العادية بسعر محسوب قدره 79.29 دولاراً للسهم من خلال إعادة استثمار الأرباح ضمن خطة MetLife للتعويض المؤجل لمديري غير التنفيذيين. بعد الصفقة تم الإبلاغ عن ملكيتها الفعلية بمقدار 22,223 سهماً مملوكة مباشرةً. تم تقديم النموذج 4 كمقدمة تقرير واحد وتوقيعه نيابةً عن الشخص المبلغ من قبل متصرف/وكيل بموجب توكيل بتاريخ 11/09/2025.

MetLife 董事 Diana McKenzie 报告了一起按 Form 4 进行的小额内幕交易。 在 2025/09/09 她通过 MetLife 面向非管理层董事的递延补偿计划,通过股息再投资获得 158 股 MetLife 普通股,价格按假定价 79.29 美元/股计算。交易完成后,其受益所有权被报告为 22,223 股,直接持有。Form 4 被作为单一报告主体提交,并于 2025/09/11 由一名代理律师代表该报告主体签署。

Positive
  • Increased direct ownership to 22,223 shares via dividend reinvestment
  • Transaction disclosed timely on Form 4 and filed by one reporting person
Negative
  • None.

Insights

TL;DR: Routine dividend reinvestment added 158 shares, marginally increasing a director's direct stake to 22,223 shares.

The reported 158-share acquisition is described as an imputed reinvestment of dividends from the company's deferred compensation plan for non-management directors. The transaction price is listed as $79.29, which is an imputed price used for recordkeeping. This is a routine, non-discretionary transaction that does not indicate new open-market buying by the director and is unlikely to be material to MetLife's valuation given the small size relative to typical public-company market capitalization.

TL;DR: Disclosure aligns with Section 16 reporting rules and shows routine plan-driven share accumulation by a director.

The filing identifies the relationship as Director and the ownership form as direct, with the acquisition resulting from the director's deferral plan. The Form 4 correctly discloses the transaction date and the mechanics: dividend reinvestment of deferred shares. The presence of an attorney-in-fact signature is consistent with administrative filing practice. There are no indications of atypical or compensatory equity grants in this report.

La direttrice di MetLife, Diana McKenzie, ha riferito un piccolo acquisto da insider ai sensi del modulo 4. Il 09/09/2025 ha ricevuto 158 azioni comuni MetLife a un prezzo imputato di 79,29 dollari per azione tramite il reinvestimento dei dividendi nell'ambito del MetLife Deferred Compensation Plan per i direttori non esecutivi. Dopo la transazione la sua titolarità beneficiaria è riportata come 22.223 azioni detenute direttamente. Il modulo 4 è stato presentato come unica persona reportante e firmato per conto del reportante da un mandatario con procura il 11/09/2025.

La directora de MetLife, Diana McKenzie, informó una pequeña adquisición de insider bajo el Formulario 4. El 09/09/2025 recibió 158 acciones de MetLife a un precio imputado de 79,29 dólares por acción mediante reinversión de dividendos en el MetLife Deferred Compensation Plan para Directores No Ejecutivos. Tras la operación, su titularidad beneficiaria se reporta en 22.223 acciones, directamente poseídas. El Formulario 4 se presentó como una única persona reportante y fue suscrito en nombre de la persona reportante por un mandatario con poder el 11/09/2025.

MetLife 이사 다이아나 맥켄지(Diana McKenzie)가 Form 4에 따른 소액 내부자 거래를 보고했습니다. 2025년 9월 9일 she는 MetLife 보통주 158주를 주당 79.29달러의 가상 가격으로 배당 재투자를 통해 받았습니다(비경영진 이사를 위한 MetLife 연금 계획). 거래 후 그녀의 유익 소유권은 직접 보유한 22,223주로 보고됩니다. Form 4는 단일 보고인으로 제출되었고 보고인 대리인이 2025년 9월 11일에 서명했습니다.

La directrice de MetLife, Diana McKenzie, a signalé une faible acquisition d’initié selon le formulaire 4. Le 09/09/2025, elle a reçu 158 actions ordinaires MetLife à un prix imputé de 79,29 USD par action grâce au réinvestissement des dividendes dans le cadre du MetLife Deferred Compensation Plan pour les administrateurs non dirigeants. Après la transaction, sa propriété bénéficiaire est déclarée à 22 223 actions détenues directement. Le formulaire 4 a été déposé en tant que personne déclarante unique et signé au nom de la personne déclarant par un mandataire le 11/09/2025.

MetLife-Direktorin Diana McKenzie meldete eine geringe Insider-Kauf unter Formular 4. Am 09/09/2025 erhielt sie 158 MetLife Stammaktien zu einem imputierten Preis von 79,29 USD pro Aktie durch Reinvestition von Dividenden im Rahmen des MetLifeDeferred Compensation Plan für nicht geschäftsführende Direktoren. Nach der Transaktion wird ihr wirtschaftliches Eigentum mit 22.223 Aktien gemeldet, direkt gehalten. Das Formular 4 wurde als Einzelmeldender eingereicht und am 11/09/2025 im Namen der meldenden Person von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MCKENZIE DIANA

(Last) (First) (Middle)
METLIFE, INC.
200 PARK AVENUE

(Street)
NEW YORK NY 10166

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/09/2025 A(1) 158 A $79.29 22,223 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
Remarks:
/s/ Taylor McInerney Jansen, Attorney-in-fact 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did MetLife director Diana McKenzie report on Form 4 (MET)?

The Form 4 reports an imputed reinvestment of dividends resulting in the acquisition of 158 shares on 09/09/2025.

How many MetLife shares does Diana McKenzie own after this transaction?

Following the reported transaction she beneficially owns 22,223 shares held directly.

What price is listed for the shares acquired on the Form 4?

The transaction shows an imputed price of $79.29 per share.

Why were the shares acquired according to the filing?

The acquisition is explained as imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors.

When was the Form 4 signed and filed?

The signature by an attorney-in-fact is dated 09/11/2025; the reported transaction date is 09/09/2025.
MetLife

NYSE:MET

MET Rankings

MET Latest News

MET Latest SEC Filings

MET Stock Data

52.69B
663.27M
0.25%
91.63%
1.37%
Insurance - Life
Life Insurance
Link
United States
NEW YORK